Payment overview · 2025
General Payments
$238.66
9 reported records · 7 companies
Healthcare provider profile · identity verified
Robert H Gerger, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · JEANNETTE, PA · NPI 1013993161
Verified facts
What the public records show
CMS Open Payments records show Robert H Gerger, D.O. received $238.66 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.59 | 41.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.11 | 17.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.86 | 12.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 8.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.95 | 7.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.92 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.01 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.44 | 8 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.11 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 75 |
| Lisinopril | Lisinopril | 297 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 59 |
| Metformin Hcl | Metformin Hcl | 249 | 37 |
| Gabapentin | Gabapentin | 239 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 42 |
| Omeprazole | Omeprazole | 204 | 53 |
| Furosemide | Furosemide | 185 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 46 |
| Lorazepam | Lorazepam | 171 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 42 |
| Famotidine | Famotidine | 166 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 36 |
| Simvastatin | Simvastatin | 144 | 32 |
| Meloxicam | Meloxicam | 137 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 32 |
| Alprazolam | Alprazolam | 122 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 37 |
| Potassium Chloride | Potassium Chloride | 112 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 21 |
| Eliquis | Apixaban | 110 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 26 |
| Allopurinol | Allopurinol | 98 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 23 |
| Sertraline Hcl | Sertraline Hcl | 78 | 17 |
| Carvedilol | Carvedilol | 73 | 13 |
| Finasteride | Finasteride | 70 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 64 | suppressed |
| Atenolol | Atenolol | 63 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 19 |
| Losartan Potassium | Losartan Potassium | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 53 | 19 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 12 |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Topiramate | Topiramate | 46 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 19 |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.66 · 9 records | PFIZER INC. | Belbuca, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error